Finished introduction, added new background section.
parent
b243989fb4
commit
1f396d856c
@ -0,0 +1,116 @@
|
|||||||
|
\documentclass[../Main.tex]{subfiles}
|
||||||
|
\graphicspath{{\subfix{Assets/img/}}}
|
||||||
|
|
||||||
|
\begin{document}
|
||||||
|
|
||||||
|
% Clinical Trials Background Outline
|
||||||
|
% - ClinicalTrials.gov
|
||||||
|
% - Clincial trial progression
|
||||||
|
% -
|
||||||
|
% -
|
||||||
|
% -
|
||||||
|
% -
|
||||||
|
% -
|
||||||
|
% -
|
||||||
|
% -
|
||||||
|
|
||||||
|
To understand how my administrative clinical trial is obtained,
|
||||||
|
let's take a look at how trial investigators record data on
|
||||||
|
\url{ClinicalTrials.gov} operate.
|
||||||
|
Figure \ref{Fig:Stages} illuistrates the process I describe below.
|
||||||
|
During the Pre-Trial period the trial investigators will design the trial,
|
||||||
|
choose primary and secondary objectives,
|
||||||
|
and decide on how many participants they need to enroll.
|
||||||
|
Once they have decided on these details, they post the trial to \url{ClinicalTrials.com}
|
||||||
|
and decide on a date to begin enrolling trial participants.
|
||||||
|
If the investigators decide to not continue with the trial before enrolling any participants,
|
||||||
|
the trial is marked as ``Withdrawn''.
|
||||||
|
On the other hand, if they begin enrolling participants, there are two methods to do so.
|
||||||
|
The first is to enter a general ``Recruiting'' state, where patients attempt to enroll.
|
||||||
|
The second is to enter an "Enrollment by invitation only" state.
|
||||||
|
After a trial has enrolled their participants, they wil typically move to an
|
||||||
|
"Active, not recruiting" state to inform potential participants that they are
|
||||||
|
not recruiting.
|
||||||
|
Finally, when the investigators have obtained enough data to achieve their primary
|
||||||
|
objective, the clinical trial will be closed, and marked as ``Completed'' in
|
||||||
|
\url{ClinicalTrials.gov}
|
||||||
|
If the trial is closed before achieving the primary objective, the trial is
|
||||||
|
marked as ``Terminated'' on
|
||||||
|
\url{ClinicalTrials.gov}.
|
||||||
|
|
||||||
|
|
||||||
|
\begin{figure}[H] %use [H] to fix the figure here.
|
||||||
|
\includegraphics[width=\textwidth]{../assets/img/ClinicalTrialStagesAndStatuses}
|
||||||
|
\par \small
|
||||||
|
Diamonds represent decision points while
|
||||||
|
Squares represent states of the clinical trial and Rhombuses represend data obtained by the trial.
|
||||||
|
\caption[Clinical Trial Stages and Progression]{Clinical Trial Stages and Progression}
|
||||||
|
\label{Fig:Stages}
|
||||||
|
\end{figure}
|
||||||
|
|
||||||
|
Note the information we obtain about the trial from the final status:
|
||||||
|
``Withdrawn'', ``Terminated'', or ``Completed''.
|
||||||
|
Although \cite{khm} describes a clinical failure due to safety or efficacy as a
|
||||||
|
\textit{scientific} failure, it is better described as a compound failure.
|
||||||
|
Discovering that a compound doesn't work as hoped is not a failure but the whole
|
||||||
|
purpose of the clinical trials process.
|
||||||
|
On the other hand, when a trial terminates early due to reasons
|
||||||
|
other than safety or efficacy concerns, the trial operator does not learn
|
||||||
|
if the drug is effective or safe.
|
||||||
|
This is a true failure in that we did not learn if the drug was effective or not.
|
||||||
|
Unfortunately, although termination documentation typically includes a
|
||||||
|
description of a reason for the clinical trial termination, this doesn't necessarily
|
||||||
|
list all the reasons contributing to the trial termination and may not exist for a given trial.
|
||||||
|
|
||||||
|
% SHOULD I EXPLAIN THE CLINICAL TRIALS DATA, i.e. AACT and SCRAPING EFFORT YET?
|
||||||
|
% For this reason we use administrative data, the records of clinical trial states, to track how trials proceed.
|
||||||
|
% There is also the issue of confounding between different
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
% \begin{enumerate}
|
||||||
|
% \item The compound demonstrates sufficient safety and efficacy, and proceeds in the appoval process.
|
||||||
|
% \label{Item:EndSuccess}
|
||||||
|
% \item The compound fails to demonstrate sufficient safety and efficacy, and the approval process halts.
|
||||||
|
% \label{Item:EndFail}
|
||||||
|
% \item The trial is terminated before it can acheive one of the first two
|
||||||
|
% outcomes, for reasons unrelated to safety and efficacy concerns.
|
||||||
|
% \label{Item:Terminate}
|
||||||
|
% \end{enumerate}
|
||||||
|
%
|
||||||
|
%
|
||||||
|
% \begin{table}
|
||||||
|
% \caption{Potential States of Knowledge from a clinical trial}\label{tab:StatesOfKnowledge}
|
||||||
|
% \begin{center}
|
||||||
|
% \begin{tabular}{p{0.15\textwidth} p{0.2\textwidth}||p{0.25\textwidth}|p{0.25\textwidth}|}
|
||||||
|
% \cline{3-4}
|
||||||
|
% \multicolumn{2}{c|}{Drug-Indication Match} & safe and efficacious & not safe or not efficatious \\
|
||||||
|
% \hline
|
||||||
|
% \hline
|
||||||
|
% \multirow{2}{0.15\textwidth}{Operations} & Success & Known good & Known bad \\
|
||||||
|
% \cline{2-4}
|
||||||
|
% & Failure & \multicolumn{2}{c|}{Unkown} \\
|
||||||
|
% \cline{2-4}
|
||||||
|
% \end{tabular}
|
||||||
|
% \end{center}
|
||||||
|
% \end{table}
|
||||||
|
%
|
||||||
|
%
|
||||||
|
% \begin{table}
|
||||||
|
% \caption{Clinical Trial end states}\label{tab:ClinicalTrialEndStates}
|
||||||
|
% \begin{center}
|
||||||
|
% \begin{tabular}{p{0.15\textwidth} p{0.2\textwidth}||p{0.25\textwidth}|p{0.25\textwidth}|}
|
||||||
|
% \cline{3-4}
|
||||||
|
% \multicolumn{2}{c|}{Drug-Indication Match} & safe and efficacious & not safe or not efficatious \\
|
||||||
|
% \hline
|
||||||
|
% \hline
|
||||||
|
% \multirow{2}{0.15\textwidth}{Operations} & Success & Completion & Completion or Termination \\
|
||||||
|
% \cline{2-4}
|
||||||
|
% & Failure & \multicolumn{2}{c|}{Termination} \\
|
||||||
|
% \cline{2-4}
|
||||||
|
% \end{tabular}
|
||||||
|
% \end{center}
|
||||||
|
% \end{table}
|
||||||
|
|
||||||
|
|
||||||
|
\end{document}
|
||||||
Loading…
Reference in New Issue